Malignant Salivary Gland Neoplasm — Trials

Malignant Salivary Gland Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 63
Recruiting: 32
Ph III recruiting: 0
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 21.4%
Trials / 1,000 deaths: 56.6 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06199453	The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial(LuRM_ACC/2023)	withdrawn	Phase 2	0	Maria Sklodowska-Curie National Research Institute of OncologyOTHER	1	Feb 10, 2025	clinicaltrials
NCT04832438	9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma	withdrawn	Phase 2	0	Actuate Therapeutics Inc.INDUSTRY